Tirzepatide vs Retatrutide: Where Each Stands

Tirzepatide and retatrutide are both made by Eli Lilly, but they sit at very different stages. Tirzepatide is an FDA-approved, available dual agonist (it activates the GLP-1 and GIP receptors), sold as Mounjaro and Zepbound. Retatrutide is an investigational triple agonist (it adds the glucagon receptor) that, as of mid-2026, is not FDA-approved and cannot be prescribed for weight loss. Early data suggests retatrutide may produce even larger weight loss, but that data is provisional.

This is a comparison of what you can use today against what may arrive later. It is general education, not medical advice, and it does not encourage seeking out an unapproved drug. Myo is not affiliated with Eli Lilly.

The mechanism: two targets vs three

The headline difference is how many gut and metabolic receptors each drug switches on. A receptor agonist is a drug that activates a receptor the way the body's own hormone would.

Tirzepatide is a dual agonist: it activates the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Retatrutide is a triple agonist, sometimes called a "triple G," that activates GLP-1, GIP, and the glucagon receptor.

That third target is the interesting part. Glucagon is best known for raising blood sugar, but in this context the glucagon-receptor action is thought to increase energy expenditure, adding a metabolic lever the dual agonists do not pull. The working hypothesis is that more receptor targets translate to more weight loss, which the trial data so far appears to support.

Tirzepatide vs retatrutide, side by side

The most important row in this table is the last data column, availability. One drug is on pharmacy shelves; the other is in trials.

Factor	Tirzepatide	Retatrutide
Receptor targets	GLP-1 + GIP (dual)	GLP-1 + GIP + glucagon (triple)
Brands	Mounjaro, Zepbound (Eli Lilly)	None; investigational
Trial weight loss	~22.5% top dose at 72 weeks (SURMOUNT-1)	~28% top dose at 80 weeks (TRIUMPH-1)
Route and frequency	Weekly subcutaneous injection	Weekly subcutaneous injection (in trials)
FDA status (mid-2026)	Approved and available	Investigational; not approved
Long-term data	Established across SURMOUNT/SURPASS programs	Limited; longer-term profile still emerging
What's still unknown	Well characterized	Real-world safety, durability, muscle effects

Sources: SURMOUNT-1 (NEJM 2022); Lilly TRIUMPH-1 press release (May 2026); retatrutide regulatory-status reporting (mid-2026).

What the data shows, with appropriate caution

The numbers are genuinely striking, and they also need careful hedging.

For tirzepatide, the evidence is mature. In SURMOUNT-1 (NEJM 2022, Jastreboff et al.), a 72-week trial in adults with obesity or overweight without type 2 diabetes, the highest dose produced about 22.5% mean weight loss versus about 2.4% on placebo. This is peer-reviewed, replicated, and reflected in real-world use.

For retatrutide, the most current data comes from the Phase 3 TRIUMPH-1 trial, announced by Eli Lilly in May 2026. In an 80-week randomized, placebo-controlled trial of roughly 2,339 adults with obesity or overweight without type 2 diabetes, the highest dose (12 mg) achieved approximately 28.3% mean weight loss (around 70 pounds) versus about 2.2% on placebo, and roughly 45% of those participants lost at least 30% of body weight. A lower 4 mg dose reached about 19%.

Two cautions matter here. First, these figures come from a company press release, with full peer-reviewed publication pending. Second, the two drugs were studied in separate trials, so the apparent gap (roughly 28% versus 22.5%) is a cross-trial comparison, not a head-to-head result. The direction is consistent with the triple-agonist hypothesis, but treat the size of the difference as suggestive rather than settled.

Availability: the difference that actually decides this

For a reader weighing options today, the mechanism is interesting but the availability is decisive. As of mid-2026, retatrutide is investigational and not FDA-approved. It cannot be prescribed for weight management, a regulatory submission was anticipated but not yet a marketed product, and any earliest approval would be later still.

Tirzepatide, by contrast, is approved and available now as Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea). If you want a triple-agonist-level effect, the honest answer in 2026 is that you wait for the data and the approval, or you work with what is available. We cover the broader landscape in our retatrutide overview and its reported side effects.

This article does not encourage sourcing unapproved or gray-market versions of retatrutide. An investigational drug without FDA approval has not cleared the agency's review for safety, efficacy, and manufacturing quality.

Side effects: similar family, less retatrutide history

Both drugs are incretin-based and share the gastrointestinal side-effect family: nausea, diarrhea, and similar effects, typically worst during dose escalation. In retatrutide trials, side effects skewed GI and appeared dose-related, much like tirzepatide and semaglutide.

The difference is the depth of the record. Tirzepatide's safety profile is well characterized across large trial programs and years of real-world use. Retatrutide's long-term safety is still being established, and the added glucagon action means there are open questions a longer track record will need to answer. For any newer, stronger agent, fatigue and weakness still warrant checking your protein and muscle, not just blaming the drug. We cover what has been reported so far in retatrutide side effects.

The triple-agonist promise, and why caution is warranted

It is worth sitting with why retatrutide generates so much excitement, and why that excitement needs guardrails.

The appeal is straightforward: if a dual agonist gets you to roughly 22% average weight loss, a triple agonist reaching toward 28% in trials suggests the ceiling for medical weight loss keeps rising. The glucagon component is the novel piece, since increasing energy expenditure is a different lever than appetite suppression alone, and it is part of why some researchers see triple agonists as a meaningful step rather than an incremental one.

The caution is equally straightforward. A drug that pulls more metabolic levers also has more ways to produce effects we do not fully understand yet at scale. Glucagon's role in glucose metabolism means its activation has to be balanced carefully, and the long-term real-world picture for a triple agonist simply does not exist yet. Trial populations are selected and monitored; the general population is not.

So the responsible framing is enthusiasm with a seatbelt on. The data is genuinely promising, and it is also early, unpublished in full, and from a single sponsor's announcement. Both things are true at once.

The muscle math does not care how many receptors

Here is the through-line. Whether a drug hits two receptors or three, the body-composition principle is the same: rapid, large weight loss puts lean mass at risk alongside fat.

Research suggests roughly 25 to 40% of total weight lost on GLP-1 medications can come from lean mass, a category that includes water and organ mass, not only skeletal muscle. A more powerful agent that drops more total weight can put more absolute lean mass on the line, which makes muscle preservation more important with stronger drugs, not less. We unpack the numbers in how much muscle you lose on Ozempic and Wegovy, and the principle scales directly to triple agonists.

Whether you are on tirzepatide today or watching retatrutide's path to approval, Myo's lean-mass tracking is the constant. It logs your dose alongside protein, resistance training, and body composition, so if a stronger drug is costing you more muscle, you see it as a trendline instead of finding out months later. Myo is a tracking and education tool, not medical advice, and it is not affiliated with Eli Lilly.

The honest bottom line

Retatrutide is the more powerful drug on paper, and the triple-agonist approach is one of the more exciting developments in this class. But "more powerful in a press release" is not the same as "available, proven, and right for you." Tirzepatide is the drug you can actually get, with a mature evidence base behind it.

Treat this as a now-versus-maybe-later comparison. Keep an eye on retatrutide's peer-reviewed data and regulatory progress, do not chase unapproved versions, and remember that the bigger the weight loss any of these drugs delivers, the more your protein and training decide whether you keep your muscle. For the full muscle-preservation playbook, start with the GLP-1 muscle loss complete guide.

References

Tirzepatide weight loss (~22.5% top dose): SURMOUNT-1 (NEJM 2022, Jastreboff et al.); Lilly SURMOUNT-1 investor release.

Retatrutide Phase 3 weight loss (~28.3% at 12 mg, 80 weeks): Lilly TRIUMPH-1 press release (May 2026); peer-reviewed publication pending.

Retatrutide investigational status (not FDA-approved as of mid-2026): GoodRx retatrutide coverage; retatrutide regulatory-status reporting (mid-2026).

Retatrutide mechanism (triple GLP-1/GIP/glucagon agonist) and GI side-effect pattern: Lilly TRIUMPH program materials; trial adverse-event reporting.

Lean-mass share of weight lost on GLP-1 medications (~25-40%): SURMOUNT-1 body-composition substudy (DOM 2025, doi:10.1111/dom.16275); STEP 1 and SUSTAIN 8 DXA analyses.